Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
نویسندگان
چکیده
PURPOSE To compare the effect of pegaptanib versus ranibizumab on exudative age-related macular degeneration (AMD) with small lesion size. METHODS This is a retrospective study of 81 eyes from 78 patients with exudative AMD treated and followed up over 12 months. Patients with baseline best corrected visual acuity (BCVA) under 20/400 and with a greatest linear dimension of lesion over 4500 μm were excluded from the study. Twenty-six eyes from 25 patients were treated with three consecutive intravitreal injections of pegaptanib (IVP group) and 55 eyes from 54 patients were treated with three consecutive ranibizumab injections (IVR group). Each therapy was repeated as needed. The alteration in BCVA was evaluated in the IVP and IVR groups. RESULTS No differences were detected in baseline parameters between the IVP and IVR groups. The mean BCVA (logMAR) at month 1, 3, 6 and 12 after the initial treatment was improved from baseline in the IVP group (-0.095, -0.17, -0.18 and -0.18, respectively) and in the IVR group (-0.077, -0.15, -0.17 and -0.11, respectively), which was statistically significant. There was no difference in the change in mean BCVA between IVP and IVR groups at the same time periods. CONCLUSIONS The visual outcome of IVP was equivalent with IVR in exudative AMD with small lesion size.
منابع مشابه
Silva Laser photocoagulation Author :
Introduction Currently, three types of therapy are approved for the treatment of exudative age-related macular degeneration (AMD): laser photocoagulation, photodynamic therapy with Verteporfin and intravitreal injections of antiangiogenic agents (Ranibizumab and Pegaptanib). Other treatments revealed to be ineffective or even more aggressive than natural disease progression. Examples of these l...
متن کاملEffect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
OBJECTIVE To determine if prophylactic use of intraocular pressure (IOP)-lowering medication is effective in reducing the IOP spikes after intravitreal injections of pegaptanib, bevacizumab, and ranibizumab. METHODS Seventy-one patients with exudative age-related macular degeneration received intravitreal injections of 1 of 3 anti-vascular endothelial growth factor medications: 30 patients re...
متن کاملEffect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
Purpose of this study was to evaluate the efficacy of switching to pegaptanib monotherapy for persistent cases of exudative age-related macular degeneration (AMD).Out of 296 eyes of 296 patients treated with ranibizumab or ranibizumab combined with photodynamic therapy (PDT), 50 eyes of 50 AMD patients were found to be resistant to these treatments. Over a 12-month period, intravitreal pegaptan...
متن کاملAnti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which was approved by the FDA at the end of 2004, was the first anti-VEGF therapy for neovascular AMD (3). After approval of bevacizumab (Genentech/ Roche) for cancer therapy and in view of the suspected role of VEGF in wet AMD, systemic intravenous and, later, intravitreal bevacizumab began to be administered off-label to treat neovascular AMD (...
متن کاملA cost-effectiveness analysis of three treatments for age-related macular degeneration.
PURPOSE The purpose of this study was to evaluate the cost effectiveness of pegaptanib sodium and ranibizumab injections compared with photodynamic therapy (PDT) with verteporfin for the treatment of choroidal neovascularization secondary to age-related macular degeneration. METHODS The analyses were performed using outcomes data from the pivotal trials for each treatment and the medicare rei...
متن کامل